Finasteride for Hair Loss: The Clinical Science of Blocking DHT and Regrowing Hair
Androgenetic alopecia — commonly called male pattern baldness — affects approximately 50% of men by age 50. It is driven not by testosterone itself, but by dihydrotestosterone (DHT): a more potent androgen produced when testosterone is converted by the enzyme 5-alpha-reductase type 2 in hair follicles and the scalp. DHT binds to androgen receptors in susceptible follicles and initiates a miniaturization process — follicles shrink progressively over years until they produce only fine, vellus hairs and eventually nothing.
Finasteride stops this process at its root.
How Finasteride Works
Finasteride is a competitive inhibitor of 5-alpha-reductase type 2. At the 1mg dose approved for hair loss, it reduces scalp DHT levels by approximately 60–70% and serum DHT by 70%. This reduction in DHT halts follicle miniaturization and, in many follicles that have not yet undergone terminal regression, can reverse the miniaturization process — producing measurable hair regrowth.
The medication does not affect testosterone levels directly. Serum testosterone may increase slightly as the DHT conversion pathway is blocked, but this is clinically insignificant for most men.
Two-Year Clinical Trial Data
The pivotal Phase III trials for finasteride 1mg enrolled 1,553 men aged 18–41 with mild-to-moderate androgenetic alopecia over two years:
90%: of finasteride-treated men showed no further hair loss progression, compared to 75% in the control group who continued to lose hair
65%: of finasteride-treated men showed increased hair growth, assessed by standardized photography and hair counts
Mean hair count (in a defined scalp area) increased by 107 hairs in the finasteride group vs. a decrease of 50 hairs in the placebo group
Long-term data from 10-year open-label extension studies shows sustained efficacy with continued use.
When to Expect Results
Finasteride requires patience. Because it halts miniaturization and supports regrowth through the natural hair cycle, visible improvement typically begins at 3–6 months and continues progressively through 12–24 months. Most physicians assess photographic response at 12 months.
Stopping finasteride reverses its effects within 6–12 months — hair loss resumes at the pre-treatment rate as DHT levels normalize.
Physician Monitoring
Blood work is not routinely required during finasteride therapy, though some providers check PSA levels at baseline in older patients. Sexual side effects — reported in a small minority of clinical trial participants — are reversible upon discontinuation in most cases.
Finasteride is a prescription medication. Not everyone qualifies. A licensed provider determines eligibility based on medical history and hair loss pattern.
